Regeneron Pharmaceuticals, Inc.

NASDAQ (USD): Regeneron Pharmaceuticals, Inc. (REGN)

Last Price

715.19

Today's Change

+2.86 (0.40%)

Day's Change

711.92 - 726.81

Trading Volume

387,390

Overview

Market Cap

77 Billion

Shares Outstanding

108 Million

Avg Volume

822,685

Avg Price (50 Days)

790.80

Avg Price (200 Days)

973.43

PE Ratio

17.68

EPS

40.46

Earnings Announcement

31-Jan-2025

Previous Close

712.33

Open

720.86

Day's Range

711.92 - 726.81

Year Range

693.0 - 1211.2

Trading Volume

460,325

Price Change Highlight

1 Day Change

0.40%

5 Day Change

0.66%

1 Month Change

-4.59%

3 Month Change

-29.51%

6 Month Change

-30.16%

Ytd Change

0.00%

1 Year Change

-22.06%

3 Year Change

14.05%

5 Year Change

93.73%

10 Year Change

73.39%

Max Change

3285.51%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment